Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
R Oerlemans, NE Franke, YG Assaraf… - Blood, The Journal …, 2008 - ashpublications.org
The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …
The resistance mechanisms of proteasome inhibitor bortezomib
S Lü, J Wang - Biomarker research, 2013 - Springer
The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the
chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy …
chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy …
Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
K Allmeroth, M Horn, V Kroef, S Miethe, RU Müller… - Leukemia, 2021 - nature.com
Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
M Ri, S Iida, T Nakashima, H Miyazaki, F Mori, A Ito… - Leukemia, 2010 - nature.com
Bortezomib is an effective agent for treating multiple myeloma (MM). To investigate the
underlying mechanisms associated with acquired resistance to this agent, we established …
underlying mechanisms associated with acquired resistance to this agent, we established …
[HTML][HTML] Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
S Lü, J Yang, Z Chen, S Gong, H Zhou, X Xu… - Experimental …, 2009 - Elsevier
OBJECTIVE: To investigate the relationship between bortezomib resistance and mutations
in the proteasome β5 subunit (PSMB5) gene. MATERIALS AND METHODS: Various …
in the proteasome β5 subunit (PSMB5) gene. MATERIALS AND METHODS: Various …
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
DI Lichter, H Danaee, MD Pickard… - Blood, The Journal …, 2012 - ashpublications.org
Variations within proteasome β (PSMB) genes, which encode the β subunits of the 20S
proteasome, may affect proteasome function, assembly, and/or binding of proteasome …
proteasome, may affect proteasome function, assembly, and/or binding of proteasome …
Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy
Bortezomib is a proteasome inhibitor important to the therapy of multiple myeloma (MM),
though a number of patients show resistance to this drug. To study the cellular basis of this …
though a number of patients show resistance to this drug. To study the cellular basis of this …
Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib
R Shringarpure, L Catley, D Bhole… - British journal of …, 2006 - Wiley Online Library
The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in
combination with conventional and other novel agents for the treatment of multiple myeloma …
combination with conventional and other novel agents for the treatment of multiple myeloma …
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
D Niewerth, GJL Kaspers, YG Assaraf… - Journal of hematology & …, 2014 - Springer
Background Despite encouraging results with the proteasome inhibitor bortezomib in the
treatment of hematologic malignancies, emergence of resistance can limit its efficacy, hence …
treatment of hematologic malignancies, emergence of resistance can limit its efficacy, hence …
[HTML][HTML] Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line
S Lü, Z Chen, J Yang, L Chen, S Gong, H Zhou… - Experimental …, 2008 - Elsevier
OBJECTIVE: To study the mechanism of bortezomib resistance in JurkatB lines derived from
T-lymphoblastic lymphoma/leukemia Jurkat line. MATERIALS AND METHODS …
T-lymphoblastic lymphoma/leukemia Jurkat line. MATERIALS AND METHODS …